We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+25.88%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.99B
AUM Growth
+$404M
Cap. Flow
-$70.3M
Cap. Flow %
-2.35%
Top 10 Hldgs %
40.51%
Holding
78
New
15
Increased
15
Reduced
16
Closed
18

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$140M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$48M
3
ABVX
Abivax
ABVX
+$43.8M
4
AMAM
Ambrx Biopharma Inc
AMAM
+$42.2M
5
TRML
Tourmaline Bio
TRML
+$36.3M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$136M
2
GPCR icon
Structure Therapeutics
GPCR
+$92.6M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$75.9M
4
IMVT icon
Immunovant
IMVT
+$66.2M
5
NVCR icon
NovoCure
NVCR
+$40.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
51
Nektar Therapeutics
NKTR
$2.39B
$10.4M 0.35%
1,226,667
– –
PRTA icon
52
PUT
Prothena Corp
PRTA
$425M
$9.09M 0.3%
250,000
– –
RLMD icon
53
Relmada Therapeutics
RLMD
$557M
$8.46M 0.28%
2,044,507
-793,311
-28% -$2.35M
ALLK
54
DELISTED
Allakos
ALLK
$6.85M 0.23%
+2,510,736
New +$5.66M
SYRS
55
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.45M 0.22%
828,485
– –
PTGX icon
56
Protagonist Therapeutics
PTGX
$8.79B
$6.31M 0.21%
+275,201
New +$4.82M
JAZZ icon
57
Jazz Pharmaceuticals
JAZZ
$15.9B
$5.94M 0.2%
48,280
-1,089,765
-96% -$136M
VIGL
58
DELISTED
Vigil Neuroscience
VIGL
$5.39M 0.18%
1,594,931
-172,200
-10% -$886K
ALGS icon
59
Aligos Therapeutics
ALGS
$26.2M
$4.05M 0.14%
+244,111
New +$4.2M
GHRS icon
60
GH Research
GHRS
$1.93B
$2.9M 0.1%
499,400
– –
ABOS icon
61
Acumen Pharmaceuticals
ABOS
$155M
– –
-2,513,044
Closed -$10.4M
AMLX icon
62
Amylyx Pharmaceuticals
AMLX
$2.26B
– –
-1,259,335
Closed -$23.1M
ATXS
63
DELISTED
Astria Therapeutics
ATXS
– –
-1,037,873
Closed -$7.74M
BEAM icon
64
Beam Therapeutics
BEAM
$2.63B
– –
-1,015,641
Closed -$24.4M
BNTX icon
65
BioNTech
BNTX
$22.9B
– –
-200,000
Closed -$21.7M
CMPS
66
Compass Pathways
CMPS
$1.53B
– –
-328,424
Closed -$2.43M
ETNB
67
DELISTED
89bio
ETNB
– –
-91,078
Closed -$1.41M
HRTX icon
68
Heron Therapeutics
HRTX
$93.9M
– –
-2,086,704
Closed -$2.15M
IPSC icon
69
Century Therapeutics
IPSC
$364M
– –
-543,008
Closed -$1.09M
MRNA icon
70
Moderna
MRNA
$21.8B
– –
-200,000
Closed -$20.7M
NBIX icon
71
Neurocrine Biosciences
NBIX
$16.8B
– –
-300,000
Closed -$33.8M
NUVB icon
72
Nuvation Bio
NUVB
$2.2B
– –
-7,720,688
Closed -$10.3M
NVAX icon
73
Novavax
NVAX
$1.2B
– –
-1,000,000
Closed -$7.24M
NVCR icon
74
NovoCure
NVCR
$1.73B
– –
-2,500,000
Closed -$40.4M
SLRN
75
DELISTED
ACELYRIN
SLRN
– –
-551,289
Closed -$5.61M
1 2
3
4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Deep Track Capital held 78 positions worth $2.99B, up 16% from $2.59B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Deep Track Capital's Q4 2023 filing shows 15 new, 15 increased, 16 reduced and 18 closed positions. Its largest new stake was argenx: 300,000 shares worth $114M. The largest sale was Jazz Pharmaceuticals, an estimated $136M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

  • Deep Track Capital's largest Q4 2023 buy was argenx: 300,000 shares worth $114M.
  • Deep Track Capital added most to Guardant Health in Q4 2023, an estimated $24.9M increase.
  • Deep Track Capital's biggest Q4 2023 reduction was Jazz Pharmaceuticals, cutting an estimated $136M.
  • Deep Track Capital fully exited NovoCure in Q4 2023, selling an estimated $40.4M.
  • Deep Track Capital's ten largest holdings make up 41% of its $2.99B portfolio in Q4 2023.
  • Deep Track Capital opened 15 new positions and closed 18 in Q4 2023.
  • Deep Track Capital's portfolio value rose 16% quarter-over-quarter to $2.99B.

Based on Deep Track Capital's 13F filing for Q4 2023, filed 14 Feb 2024.